A multi-center, placebo-controlled, randomized Phase 2 study of Triplex for control of CMV in patients undergoing liver transplantation

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 According to a Helocyte media release, the company announced that the National Cancer Institute has awarded a 3.22 million dollars grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.
30 Mar 2023 According to a Fortress Biotech media release, enrollment is expected to begin this year and the company believes this data set could ultimately be used to support approval of Triplex in this setting.
19 Aug 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com